Cenna Biosciences, Inc. is a privately-held biopharmaceutical company in La Jolla CA, focused on the discovery and development of novel drugs for the prevention and treatment of Alzheimer’s disease (AD). The Company was founded in 2006 to translate over a decade’s academic research at UC San Diego by the Founders who became independent of UC San Diego in 2011. Disease-modifying therapies for AD are urgently needed. There is a huge and growing market and patient population worldwide and there is no disease-modifying drug available. Cenna has a novel and different proprietary patented technology that arrests the underlying cause of the disease and that addresses previous failures by others. IND filing of Cenna’s first-in-class lead peptide drug candidate is planned within the next six months. Funding to date by Founders and $21M in NIH grants. The Company is seeking a $15 M investment to prepare an IND package and carry out Phase 1 clinical trials.